For instance, blocking antibodies targeting Clever-1 or ETBR, which are key surface molecules involved in Treg cell transmigration across tumor vasculature, impaired Treg cell but not CD8+ T cell entry into tumors (10, 103, 108). Here, CD8A is linked to neoplasm.